表紙
市場調查報告書

全球感染疾病市場

Communicable Disease Market: A BCC Research Overview

出版商 BCC Research 商品編碼 900629
出版日期 內容資訊 英文 151 Pages
訂單完成後即時交付
價格
Back to Top
全球感染疾病市場 Communicable Disease Market: A BCC Research Overview
出版日期: 2019年07月31日內容資訊: 英文 151 Pages
簡介

全球感染疾病市場規模,預計從2019年到2024年以3.8%的年複合成長率成長,預計從2019年的577億美元到2024年達到694億美元

本報告提供全球感染疾病市場相關調查,醫療保健產業上全球感染疾病市場概要,世界市場趨勢、成果資料、年複合成長率預測,地區市場分析,法規情形,競爭情形的討論,及全面的簡介等系統性資訊。

第1章 簡介

第2章 摘要、亮點

第3章 市場、技術背景

  • 疾病概要
  • HIV
  • 披衣菌感染
  • 生殖器皰疹
  • 淋病
  • A型/B型/C型肝炎
  • HPV
  • 梅毒
  • 瘧疾
  • 結核
  • 流感
  • 毛滴蟲屬症
  • 疥瘡
  • 細菌性陰道炎
  • 念珠菌症
  • 性病潰瘍
  • 陰蝨症

第4章 市場動態

  • 市場成長的推動要素
  • 市場成長的阻礙因素
  • STD用產前檢查的不足

第5章 市場分析:各疾病類型

  • 全球感染疾病市場:各疾病
  • HIV
  • B型/C型肝炎
  • 單純皰疹病毒
  • 流感
  • 瘧疾
  • 結核
  • 其他

第6章 市場分析:各地區

  • 全球感染疾病市場:各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第7章 開發平台分析

  • 概要
  • B型/C型肝炎
  • 單純皰疹病毒
  • HIV/AIDS
  • 流感A型/B型
  • RS病毒
  • 瘧疾
  • 結核
  • MERS
  • 出血熱
    • 登革熱
    • 伊波拉熱
    • 賴薩熱
    • 馬爾堡熱
    • 黃熱
    • 茲卡熱

第8章 法規、醫療費償付

第9章 競爭情形

  • 性感染疾病 (STD) 治療藥:全球競爭企業分析
  • 流感治療藥:全球競爭企業分析

第10章 企業簡介

  • ABBOTT LABORATORIES
  • ABBVIE INC.
  • ASTRAZENECA/MEDIMMUNE
  • AUROBINDO PHARMA LTD.
  • BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
  • BRISTOL-MYERS SQUIBB CO.
  • CIPLA INC.
  • DAIICHI SANKYO
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE PLC
  • JANSSEN PHARMACEUTICALS, INC.
  • MERCK & CO., INC.
  • MITSUBISHI TANABE PHARMA CORP.
  • MYLAN LABORATORIES
  • NOVARTIS AG
  • PFIZER INC.
  • HOFFMANN-LA ROCHE INC.
  • SANOFI, SANOFI PASTEUR
  • SEQIRUS, A CSL COMPANY
  • VIIV HEALTHCARE

第11章 附錄:縮寫

目錄
Product Code: PHM216A

Report Highlights:

The global market for communicable disease should grow from $57.7 billion in 2019 to $69.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.8% for the period of 2019-2024.

North American market for communicable disease should grow from $21.9 billion in 2019 to reach $25.9 billion by 2024 at a CAGR of 3.4% for the period of 2019-2024.

Asia-Pacific market for communicable disease should grow from $11.7 billion in 2019 to reach $14.9 billion by 2024 at a CAGR of 5.0% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers therapeutics used in treatment of communicable diseases. The report highlights the current and future market potential of communicable diseases therapeutics and provides a detailed analysis of the competitive environment, regulations, epidemiology of communicable diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.

The report details market shares of communicable diseases based on different disease indication. Based on disease indication the market is segmented into HIV, Hepatitis B&C, Herpes Simplex Virus, Influenza, Malaria, Tuberculosis, and Others.

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

  • 23 data tables and 24 additional tables
  • Detailed overview of the global market for communicable diseases within the healthcare industry
  • Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Regional analysis of the communicable disease market, covering North America, Europe, Asia-Pacific, South America and Middle East & Africa
  • A look at the government regulations pertaining to drug developments for communicable diseases and pipeline analysis covering ongoing clinical trials and promising forthcoming therapies in late stage
  • Discussion of competitive landscape, mergers and acquisitions of companies to enhance their product portfolio, and future commercial marketplace
  • Comprehensive company profiles of major market players, including Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, Novartis AG and Pfizer Inc.

Table of Contents

Chapter 1 - Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 - Summary and Highlights

Chapter 3 - Market and Technology Background

  • Disease Overview
  • HIV
    • HIV Timeline and Milestones
    • HIV Life Cycle: Treatment and Mechanism of Action
    • HIV Prophylaxis
    • Epidemiology
  • Chlamydia
    • Epidemiology
  • Genital Herpes
    • Epidemiology
  • Gonorrhea
    • Epidemiology
  • Hepatitis A, B and C
    • Epidemiology
  • HPV
  • Syphilis
    • Epidemiology
  • Malaria
    • Incidence and Geographical Distribution
  • Tuberculosis
    • Incidence and Geographical Distribution
  • Influenza
    • Incidence and Mortality
  • Trichomoniasis
  • Scabies
  • Bacterial Vaginosis
  • Candidiasis
  • Chancroid (Venereal Ulcers)
  • Pediculosis Pubis

Chapter 4 - Market Dynamics

  • Market Drivers
    • Regional Awareness Program for Communicable Diseases
    • Development of Novel Therapies
    • Public Private Partnership
    • Global Program to Counter HIV
    • Increasing Prevalence of Communicable Diseases
  • Market Restraints
    • Social Stigma Associated with STD
    • High Cost of Treatment
    • Underestimating the Risk of Contracting the Disease
  • Lack of Prenatal Screenings for STD

Chapter 5 - Market Breakdown by Disease Type

  • Global Market for Communicable Disease, by Disease Indication
  • HIV
    • Market Size and Forecast
    • Market Analysis
  • Hepatitis B&C
    • Market Size and Forecast
    • Market Analysis
  • Herpes Simplex Virus
    • Market Size and Forecast
    • Market Analysis
  • Influenza
    • Market Size and Forecast
    • Market Analysis
  • Malaria
    • Market Size and Forecast
    • Market Analysis
  • Tuberculosis
    • Market Size and Forecast
    • Market Analysis
  • Others
    • Market Size and Forecast
    • Market Analysis

Chapter 6 - Market Breakdown by Region

  • Global Market for Communicable Disease, by Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • South America
  • Middle East & Africa

Chapter 7 - Pipeline Analysis

  • Overview
  • Hepatitis B and Hepatitis C
  • Herpes Simplex Virus
  • HIV/AIDS
  • Influenza A and Influenza B
  • Respiratory Syncytial Virus
  • Malaria
  • Tuberculosis
  • MERS
  • Hemorrhagic Fevers
    • Dengue
    • Ebola
    • Lassa fever
    • Marburg
    • Yellow Fever
    • Zika

Chapter 8 - Regulation and Reimbursement

  • Regulations
    • U.S.
    • Europe
    • Japan
    • China
  • Pricing and Reimbursement
    • U.S.
    • Europe
    • Japan

Chapter 9 - Competitive Landscape

  • Sexually Transmitted Disease Therapeutics: Global Competitor Analysis
  • Influenza Therapeutics: Global Competitor Analysis

Chapter 10 - Company Profiles

  • ABBOTT LABORATORIES
  • ABBVIE INC.
  • ASTRAZENECA/MEDIMMUNE
  • AUROBINDO PHARMA LTD.
  • BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
  • BRISTOL-MYERS SQUIBB CO.
  • CIPLA INC.
  • DAIICHI SANKYO
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE PLC
  • JANSSEN PHARMACEUTICALS, INC.
  • MERCK & CO., INC.
  • MITSUBISHI TANABE PHARMA CORP.
  • MYLAN LABORATORIES
  • NOVARTIS AG
  • PFIZER INC.
  • HOFFMANN-LA ROCHE INC.
  • SANOFI, SANOFI PASTEUR
  • SEQIRUS, A CSL COMPANY
  • VIIV HEALTHCARE

Chapter 11 - Appendix: Acronyms

List of Tables

  • Summary Table: Global Communicable Disease Market, by Region, Through 2024
    • Table 1: Milestones in the History of HIV
    • Table 2: Life Cycle of HIV Therapeutics Target Points
    • Table 3: HIV Incidence, by Country, 2005-2016
    • Table 4: HIV Incidence, by Country, 2014-2017
    • Table 5: Chlamydia Incidence, by Country, 2012-2017
    • Table 6: Global HSV-1 Prevalence Aged 0-49 years, by Region, 2012
    • Table 7: Gonorrhea Epidemiology, by Country, 2012-2017
    • Table 8: Hepatitis A Incidence, by Country, 2012-2017
    • Table 9: Hepatitis B Incidence, by Country, 2012-2017
    • Table 10: Hepatitis C Incidence, by Country, 2012-2015
    • Table 11: Syphilis Incidence, by Country, 2013-2016
    • Table 12: Infectious Syphilis Incidence, by Country, 2012-2014
    • Table 13: Suspected Malaria Cases, by WHO Region, 2010-2015
    • Table 14: Confirmed Malaria Cases, by WHO Region, 2010-2015
    • Table 15: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010
    • Table 16: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type and Manufacturer
    • Table 17: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer
    • Table 18: Global Communicable Disease Market, by Disease Indication, Through 2024
    • Table 19: Global HIV Therapeutics Market, by Drug Class, Through 2024
    • Table 20: ART Therapy Coverage, by Region, 2017
    • Table 21: North American Estimated HBsAG Seroprevalence, 2016
    • Table 22: Drug for Chlamydia Treatment
    • Table 23: Drug for Gonorrhea Treatment
    • Table 24: Global Communicable Disease Market, by Region, Through 2024
    • Table 25: North American Communicable Disease Market, by Country, Through 2024
    • Table 26: European Communicable Disease Market, by Country/Region, Through 2024
    • Table 27: Asia-Pacific Communicable Disease Market, by Country/Region, Through 2024
    • Table 28: South American Estimated HBsAG Seroprevalence, by Country, 2016
    • Table 29: Hepatitis B and Hepatitis C Development Pipeline and Recent Launches, 2019
    • Table 30: Herpes Simplex Virus Development Pipeline and Recent Launches, 2019
    • Table 31: HIV/AIDS Development Pipeline and Recent Launches, 2019
    • Table 32: Influenza A and Influenza B Development Pipeline and Recent Launches, 2019
    • Table 33: RSV Development Pipeline and Recent Launches, 2019
    • Table 34: Malaria Development Pipeline and Recent Launches, 2019
    • Table 35: Tuberculosis Development Pipeline and Recent Launches, 2019
    • Table 36: MERS Development Pipeline and Recent Launches, 2019
    • Table 37: Dengue Development Pipeline and Recent Launches, 2019
    • Table 38: Ebola Development Pipeline and Recent Launches, 2019
    • Table 39: Lassa Fever Development Pipeline and Recent Launches, 2019
    • Table 40: Marburg Development Pipeline and Recent Launches, 2019
    • Table 41: Yellow Fever Development Pipeline and Recent Launches, 2019
    • Table 42: Zika Development Pipeline and Recent Launches, 2019
    • Table 43: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing
    • Table 44: Preventive Health Services for Children Covered by Private Plans without Cost Sharing
    • Table 45: Global Market Share Analysis for Sexually Transmitted Disease Therapeutics, by Company, 2019
    • Table 46: Acronyms Used in This Report

List of Figures

  • Summary Figure: Global Communicable Disease Market Share, by Region, 2018
    • Figure 1: Types of Drug Failure Encountered During HIV Treatment
    • Figure 2: Global Historic and Current HIV Prevalence Trend, 2012-2016
    • Figure 3: Estimated HIV Regional Prevalence, 2016
    • Figure 4: Estimated HIV Regional Incidence, 2016
    • Figure 5: Global Historic and Current Chlamydia Incidence Women Trend, 2012-2014
    • Figure 6: Global Historic and Current Chlamydia Incidence Men Trend, 2012-2014
    • Figure 7: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
    • Figure 8: Global Historic and Current Gonorrhea Incidence Women Trend, 2012-2014
    • Figure 9: Hepatitis Timeline, 1990-2004
    • Figure 10: Hepatitis Timeline, 2011-2015
    • Figure 11: Hepatitis Timeline, 2015-2017
    • Figure 12: U.S. Syphilis Incidence Among Newborns, 2014-2016
    • Figure 13: Global Historic and Current Infectious Syphilis Incidence Men Trend, 2012-2014
    • Figure 14: Global Prevalence of Tuberculosis, 1990-2015
    • Figure 15: Global Incidence of Tuberculosis, 1990-2015
    • Figure 16: U.S. Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017
    • Figure 17: Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016
    • Figure 18: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
    • Figure 19: Global Communicable Disease Market, by Disease Indication, 2018-2024
    • Figure 20: Global HIV Market, 2018-2024
    • Figure 21: Global Prevalence of HIV, by Region, 2016
    • Figure 22: Global Incidence of HIV, by Region, 2016
    • Figure 23: Global Hepatitis Market, 2018-2024
    • Figure 24: Global Herpes Simplex Virus Market, 2018-2024
    • Figure 25: Global Market for HSV Therapeutics, by WHO Region, 2016-2022
    • Figure 26: Global Influenza Market, 2018-2024
    • Figure 27: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017
    • Figure 28: Global Malaria Market, 2018-2024
    • Figure 29: Global Tuberculosis Market, 2018-2024
    • Figure 30: Global Others Market, 2018-2024
    • Figure 31: Global Communicable Disease Market Share, by Region, 2018
    • Figure 32: North American Communicable Disease Market, 2018-2024
    • Figure 33: North American Communicable Disease Market Share, by Country, 2018
    • Figure 34: U.S. Communicable Disease Market, 2018-2024
    • Figure 35: Canadian Communicable Disease Market, 2018-2024
    • Figure 36: Mexican Communicable Disease Market, 2018-2024
    • Figure 37: European Communicable Disease Market Share, by Country/Region, 2018
    • Figure 38: German Communicable Disease Market, 2018-2024
    • Figure 39: French Communicable Disease Market, 2018-2024
    • Figure 40: French Historic and Current Chlamydia Incidence Trend, 2011-2015
    • Figure 41: French Historic and Current Gonorrhea Incidence Trend, 2011-2015
    • Figure 42: U.K. Communicable Disease Market, 2018-2024
    • Figure 43: Spanish Communicable Disease Market, 2018-2024
    • Figure 44: Italian Communicable Disease Market, 2018-2024
    • Figure 45: Rest of European Communicable Disease Market, 2018-2024
    • Figure 46: Asia-Pacific Communicable Disease Market Share, by Country/Region, 2018
    • Figure 47: Japanese Communicable Disease Market, 2018-2024
    • Figure 48: Japanese Historic and Current HIV/AIDS Infections Incidence, 2001-2016
    • Figure 49: Chinese Communicable Disease Market, 2018-2024
    • Figure 50: Indian Communicable Disease Market, 2018-2024
    • Figure 51: Rest of Asia-Pacific Communicable Disease Market, 2018-2024
    • Figure 52: South American Communicable Disease Market, 2018-2024
    • Figure 53: Middle East and African Communicable Disease Market, 2018-2024
    • Figure 54: Global Influenza Therapeutics Market Share, by Manufacturer, 2018
    • Figure 55: Global Competitor Market Analysis for Influenza Therapeutics, 2018
Back to Top